

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



*(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)  
(Stock Code: 01099)*

**ANNOUNCEMENT  
PRINCIPAL FINANCIAL DATA OF CNMDC  
FOR THE YEAR ENDED 31 DECEMBER 2025**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement dated 19 March 2026 (the “**Announcement**”) issued by Sinopharm Group Co. Ltd. (the “**Company**”) in relation to the annual report of China National Medical Device Co., Ltd. (中國醫療器械有限公司) (“**CNMDC**”), a subsidiary of the Company, for the year ended 31 December 2025 issued by CNMDC on the websites of China Money and Shanghai Clearing House.

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal audited financial data of CNMDC for the year ended 31 December 2025 as set out in the Announcement.

*\* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*

# PRINCIPAL FINANCIAL DATA OF THE CONSOLIDATED FINANCIAL STATEMENTS

Unit: Yuan

Currency: RMB

|                                                                         | The year of 2025       | The year of 2024       | Changes of this year compared with last year |
|-------------------------------------------------------------------------|------------------------|------------------------|----------------------------------------------|
| Revenue                                                                 | 74,892,761,889.78      | 76,698,316,757.24      | -2.35%                                       |
| Operating profit                                                        | 1,248,513,736.69       | 1,219,453,089.52       | 2.38%                                        |
| Total comprehensive income attributable to owners of the parent company | 506,755,640.47         | 403,336,362.93         | 25.64%                                       |
| Net cash flow arising from operating activities                         | 738,641,094.58         | -1,356,284,840.11      | -154.46%                                     |
|                                                                         | As at 31 December 2025 | As at 31 December 2024 | Changes of 2025 year-end over 2024 year-end  |
| Total assets                                                            | 57,302,220,888.25      | 61,661,013,678.38      | -7.07%                                       |
| Total equity attributable to owners of the parent company               | 8,300,052,155.36       | 7,884,395,529.18       | 5.27%                                        |

By order of the Board  
**Sinopharm Group Co. Ltd.**  
**Jin Bin**  
*Chairman*

Shanghai, the PRC  
19 March 2026

*As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.*